276 related articles for article (PubMed ID: 29153095)
1. Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer.
Vietsch EE; Graham GT; McCutcheon JN; Javaid A; Giaccone G; Marshall JL; Wellstein A
Cancer Genet; 2017 Dec; 218-219():39-50. PubMed ID: 29153095
[TBL] [Abstract][Full Text] [Related]
2. Reprint of: Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer.
Vietsch EE; Graham GT; McCutcheon JN; Javaid A; Giaccone G; Marshall JL; Wellstein A
Cancer Genet; 2018 Dec; 228-229():131-142. PubMed ID: 30447903
[TBL] [Abstract][Full Text] [Related]
3. Somatic alterations in circulating cell-free DNA of oesophageal carcinoma patients during primary staging are indicative for post-surgical tumour recurrence.
Pasternack H; Fassunke J; Plum PS; Chon SH; Hescheler DA; Gassa A; Merkelbach-Bruse S; Bruns CJ; Perner S; Hallek M; Büttner R; Bollschweiler E; Hölscher AH; Quaas A; Zander T; Weiss J; Alakus H
Sci Rep; 2018 Oct; 8(1):14941. PubMed ID: 30297788
[TBL] [Abstract][Full Text] [Related]
4. Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma.
Affolter KE; Hellwig S; Nix DA; Bronner MP; Thomas A; Fuertes CL; Hamil CL; Garrido-Laguna I; Scaife CL; Mulvihill SJ; Underhill HR
Neoplasia; 2021 Sep; 23(9):859-869. PubMed ID: 34298235
[TBL] [Abstract][Full Text] [Related]
5. Analysis of colorectal cancer-related mutations by liquid biopsy: Utility of circulating cell-free DNA and circulating tumor cells.
Takeda K; Yamada T; Takahashi G; Iwai T; Ueda K; Kuriyama S; Koizumi M; Matsuda A; Shinji S; Ohta R; Yokoyama Y; Hotta M; Hara K; Yoshida H
Cancer Sci; 2019 Nov; 110(11):3497-3509. PubMed ID: 31465598
[TBL] [Abstract][Full Text] [Related]
6. Utility of KRAS mutation detection using circulating cell-free DNA from patients with colorectal cancer.
Yamada T; Iwai T; Takahashi G; Kan H; Koizumi M; Matsuda A; Shinji S; Yamagishi A; Yokoyama Y; Tatsuguchi A; Kawagoe T; Kitano S; Nakayama M; Matsumoto S; Uchida E
Cancer Sci; 2016 Jul; 107(7):936-43. PubMed ID: 27116474
[TBL] [Abstract][Full Text] [Related]
7. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
[TBL] [Abstract][Full Text] [Related]
8. Automated size selection for short cell-free DNA fragments enriches for circulating tumor DNA and improves error correction during next generation sequencing.
Hellwig S; Nix DA; Gligorich KM; O'Shea JM; Thomas A; Fuertes CL; Bhetariya PJ; Marth GT; Bronner MP; Underhill HR
PLoS One; 2018; 13(7):e0197333. PubMed ID: 30044795
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of EGFR Mutation Load in Plasma for Prediction of Treatment Response and Disease Progression in Patients With EGFR-Mutant Lung Adenocarcinoma.
Taus Á; Camacho L; Rocha P; Hardy-Werbin M; Pijuan L; Piquer G; López E; Dalmases A; Longarón R; Clavé S; Salido M; Albanell J; Bellosillo B; Arriola E
Clin Lung Cancer; 2018 Sep; 19(5):387-394.e2. PubMed ID: 29656868
[TBL] [Abstract][Full Text] [Related]
10. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
[TBL] [Abstract][Full Text] [Related]
11. Optimization of Sources of Circulating Cell-Free DNA Variability for Downstream Molecular Analysis.
Till JE; Black TA; Gentile C; Abdalla A; Wang Z; Sangha HK; Roth JJ; Sussman R; Yee SS; O'Hara MH; Thompson JC; Aggarwal C; Hwang WT; Elenitoba-Johnson KSJ; Carpenter EL
J Mol Diagn; 2021 Nov; 23(11):1545-1552. PubMed ID: 34454115
[TBL] [Abstract][Full Text] [Related]
12. Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia.
Short NJ; Patel KP; Albitar M; Franquiz M; Luthra R; Kanagal-Shamanna R; Wang F; Assi R; Montalban-Bravo G; Matthews J; Ma W; Loghavi S; Takahashi K; Issa GC; Kornblau SM; Jabbour E; Garcia-Manero G; Kantarjian HM; Estrov Z; Ravandi F
Blood Adv; 2020 Apr; 4(8):1670-1677. PubMed ID: 32324887
[TBL] [Abstract][Full Text] [Related]
13. Methods for Measuring ctDNA in Lymphomas.
Rossi D; Condoluci A; Spina V; Gaidano G
Methods Mol Biol; 2019; 1881():253-265. PubMed ID: 30350211
[TBL] [Abstract][Full Text] [Related]
14. Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows.
Lampignano R; Neumann MHD; Weber S; Kloten V; Herdean A; Voss T; Groelz D; Babayan A; Tibbesma M; Schlumpberger M; Chemi F; Rothwell DG; Wikman H; Galizzi JP; Riise Bergheim I; Russnes H; Mussolin B; Bonin S; Voigt C; Musa H; Pinzani P; Lianidou E; Brady G; Speicher MR; Pantel K; Betsou F; Schuuring E; Kubista M; Ammerlaan W; Sprenger-Haussels M; Schlange T; Heitzer E
Clin Chem; 2020 Jan; 66(1):149-160. PubMed ID: 31628139
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor mutation status in cell-free DNA supernatant of bronchial washings and brushings.
Kawahara A; Fukumitsu C; Taira T; Abe H; Takase Y; Murata K; Yamaguchi T; Azuma K; Ishii H; Takamori S; Akiba J; Hoshino T; Kage M
Cancer Cytopathol; 2015 Oct; 123(10):620-8. PubMed ID: 26235264
[TBL] [Abstract][Full Text] [Related]
16. Detection of circulating tumor DNA by digital droplet PCR in resectable lung cancer as a predictive tool for recurrence.
Gassa A; Fassunke J; Schueten S; Kuhlmann L; Scherer M; Qien J; Zhao Y; Michel M; Loeser H; Wolf J; Buettner R; Doerr F; Heldwein M; Hagmeyer L; Frank K; Merkelbach-Bruse S; Quaas A; Bruns C; Hekmat K; Weiss J; Wahlers T; Alakus H
Lung Cancer; 2021 Jan; 151():91-96. PubMed ID: 33257044
[TBL] [Abstract][Full Text] [Related]
17. Circulating cell-free DNA-based biomarkers for prognostication and disease monitoring in adrenocortical carcinoma.
Lippert J; Smith G; Appenzeller S; Landwehr LS; Prete A; Steinhauer S; Asia M; Urlaub H; Elhassan YS; Kircher S; Arlt W; Fassnacht M; Altieri B; Ronchi CL
Eur J Endocrinol; 2024 Mar; 190(3):234-247. PubMed ID: 38451242
[TBL] [Abstract][Full Text] [Related]
18. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
[No Abstract] [Full Text] [Related]
19. Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer.
Riva F; Dronov OI; Khomenko DI; Huguet F; Louvet C; Mariani P; Stern MH; Lantz O; Proudhon C; Pierga JY; Bidard FC
Mol Oncol; 2016 Mar; 10(3):481-93. PubMed ID: 26856794
[TBL] [Abstract][Full Text] [Related]
20. Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen.
Jansen MP; Martens JW; Helmijr JC; Beaufort CM; van Marion R; Krol NM; Monkhorst K; Trapman-Jansen AM; Meijer-van Gelder ME; Weerts MJ; Ramirez-Ardila DE; Dubbink HJ; Foekens JA; Sleijfer S; Berns EM
Oncotarget; 2016 Jul; 7(28):43412-43418. PubMed ID: 27270325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
